Who are Vitamin D3 cholecalciferol)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SODIUM ASCORBATE, Infuvite Adult, Hectorol, Zemplar, Fosamax, Dovonex.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vitamin-d3-cholecalciferol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Vitamin D3 cholecalciferol) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vitamin D3 cholecalciferol) (Vitamin D3 cholecalciferol)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin D [EPC].

marketed Vitamin D [EPC] Small molecule Live · refreshed every 30 min

Target snapshot

Vitamin D3 cholecalciferol) (Vitamin D3 cholecalciferol)) — Abramson Cancer Center at Penn Medicine.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vitamin D3 cholecalciferol) TARGET	Vitamin D3 cholecalciferol)	Abramson Cancer Center at Penn Medicine	marketed	Vitamin D [EPC]
SODIUM ASCORBATE	SODIUM ASCORBATE		marketed	Vitamin D [EPC]		2006-01-01
Infuvite Adult	Colecalciferol	Novartis	marketed	Vitamin D	Vitamin D3 receptor	2000-01-01
Hectorol	DOXERCALCIFEROL	Sanofi	marketed	Vitamin D2 Analog [EPC]	Vitamin D3 receptor	1999-01-01
Zemplar	PARICALCITOL	AbbVie	marketed	Vitamin D2 Analog [EPC]	Vitamin D3 receptor	1998-01-01
Fosamax	ALENDRONIC ACID	Merck And Co Inc	marketed	Vitamin D [EPC]	Farnesyl pyrophosphate synthase	1995-01-01
Dovonex	CALCIPOTRIENE		marketed	Vitamin D Analog [EPC]	Vitamin D3 receptor	1993-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-05-26 — Dovonex · 8629128 · Formulation · US
2028-05-07 — Dovonex · 8263580 · Formulation · US
2031-12-05 — Fosamax · 9592195 · US

Sponsor landscape (Vitamin D [EPC] class)

· 2 drugs in this class
Abramson Cancer Center at Penn Medicine · 1 drug in this class
Eli Lilly · 1 drug in this class
Heather Wakelee · 1 drug in this class
Merck And Co Inc · 1 drug in this class
Mohammed Milhem, MBBS · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vitamin D3 cholecalciferol) — Competitive Intelligence Brief. https://druglandscape.com/ci/vitamin-d3-cholecalciferol. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab